Maze Therapeutics, Inc. Overview
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Sector: Health Care
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating varian
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingResearch snapshot
This Mavefund research page organizes verified information for Maze Therapeutics, Inc. (MAZE), including the company profile, price history, source-linked filings, available financial statements, research signals, and risks to review.
- Listing
- MAZE · Nasdaq · MIC XNAS
- Country
- United States
- Trading currency
- USD
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Primary sources
Coverage is refreshed automatically and published only after data-integrity validation. Research support only; not personalized financial advice.
Reported Results
No latest earnings report cached yet
The latest source-linked annual or interim company filing has not been cached for this ticker yet.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported filing facts, organized and linked to the original source.
Annual 10-K, 20-F, or ESEF financial statement data is not available yet.
Source details load with the filing data. Values are standardized company disclosures for research support, not personalized financial advice.